New data on the potential of sebetralstat presented at the recent German Allergy Congress

The latest data on a new medicine for HAE, called Ekterly (sebetralstat), was presented at the 20th German Allergy Congress in Düsseldorf, Germany between 2-4 October 2025. Across multiple presentations, sebeltralstat demonstrated the ability to rapidly halt the progression of HAE attacks, deliver fast symptom relief and address key barriers associated with injectable therapies. Additional survey findings from German patients further highlight the urgent need for access to innovative on-demand HAE treatments across Europe.

Paul Audhya, MD, MBA, Chief Medical Officer of KalVista, said: “The data presented underscore the potential of EKTERLY for people living with HAE and highlight the urgent need for innovation across Europe. As we’ve seen in the US, patients in Germany delay or avoid on-demand treatment due to the challenges associated with injectable on-demand treatments, including injection-site reactions and the inability to readily access medication. An oral on-demand treatment has the ability to empower patients to better manage their condition, enabling earlier treatment of more attacks.

“With EKTERLY now approved in the European Union, we look forward to bringing this innovation to more people living with HAE—beginning with a launch in Germany this quarter, followed by additional European launches in 2026 and beyond.”

(Source: KalVista)